[Use of prodigiozan for the prevention of acute respiratory diseases and its effect on the course of convalescence in children].
D000208:Acute Disease; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001798:Blood Proteins / Q000032:analysis; D002097:C-Reactive Protein / Q000032:analysis; D002648:Child; D002675:Child, Preschool; D003289:Convalescence; D003864:Depression, Chemical; D005260:Female; D006023:Glycoproteins / Q000097:blood; D006801:Humans; D006940:Hyperemia / Q000188:drug therapy; D007223:Infant; D008297:Male; D010587:Phagocytosis / Q000187:drug effects; D011135:Polysaccharides, Bacterial / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011414:Properdin / Q000097:blood; D012141:Respiratory Tract Infections / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control*; D012220:Rhinitis / Q000188:drug therapy; D012706:Serratia marcescens; D013268:Stimulation, Chemical; D014455:Ukraine
D000970:Antineoplastic Agents; D001798:Blood Proteins; D006023:Glycoproteins; D011135:Polysaccharides, Bacterial; D011414:Properdin; D002097:C-Reactive Protein
Primeneie prodigiozana s tsel'iu profilaktiki ostrykh respiratornykh zabolevanii i vliianie ego na techenie perioda rekonvalestsentsii u perebolevshikh detei.